10.11.2005
Free Trade
Agreeement - Joint Collaboration and partnership
Gammasonics Institute
for Medical Research Pty Ltd & Landauer, Inc.
- Australia/USA
A joint collaboration
and partnership between Landauer and Gammasonics was
signed on the 10th November of 2005, in the presence
of NSW Members of Parliament, senior personnel from
the department of state development, and other at
NSW Parliament House.
We understand this is the first of such bilateral
agreements signed since the Free Trade Agreement by
the Australian and USA governments.
The joint venture is significant, not only to Gammasonics,
but also for the Australian biotechnology industry.
This is the first time that an Australian organisation
has been recognized in such a sensitive area of medical
and scientific radiation, and to work closely with
one of the high profile corporations from the United
States, as Landauer is.
Landauer is listed on the New York Stock Exchange,
and is a world leader in personal radiation dosimetry,
with a current database of more than 45 million readings
per year. This makes them by far the largest in the
world. By comparison, our largest local service provider
of older technology, provide approximately 150,000
readings a year.
Landauer holds the world patent for OSL (Optically
Stimulated Luminescence) technology. This knowledge
has been shared with Gammasonics Institute for Medical
research for the developing application of new technology
and equipment that has not been explored until now.
The agreement includes; Establishment of private dosimetry
systems across Asia and the Middle East, Australia
to provide teaching facilities for the new technology,
Landauer to be the distributor of the technology in
the northern Hemisphere. The new technology to target
environmental, medical and diagnostic applications
along with military and national anti-terrorism security
applications.
Gammasonics is already well know in every corner of
the world by the success of the Gamma probe which
we launched in the mid 1990’s, helping more than 100,000
patients undergo a less radical cancer treatment,
with a proven success rate of 98%. At the same time,
Gammasonics’ current technology, produced in Australia,
will be distributed by Landauer throughout the United
States, Japan, China and Europe.
In view of this, the group is currently training multilingual
personnel with technical and commercial skills, with
one moto, “we speak your language”.
